The potential of targeting GPR35 in a therapeutic context is supported in part by genetic associations that have suggested roles in diseases including ulcerative colitis and primary sclerosing cholangitis (Ellinghaus et al.,2013; Yang et al.,2015), and GPR35 is highly expressed in regions of, particularly, the lower gut and colon and by various white cell groups, including numerous dendritic cell and monocyte populations. Here, GPR35 is linked to ulcerative colitis.